pembrolizumab,lenvatinib
eisai,merck
['hcc', 'leap-002', 'pembro', 'lenva']
results from #esmo22 phase 3 leap-002 of #lenvatinib + #pembro for #hcc #hepatocellular #cancer was for the combo for os. dfs and rr of 26% vs 17.5% #cancer #immunotherapy #livercancer 
Co-Director/Co-Leader GI Oncology Research; Director, Young Adult Cancers Program; Co-Chair, NCI GI Steering Committee; and Director for Strategic Relations